PCM
AGIO icon

Portolan Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Portolan Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-40,261
Closed -$1.69M – 111
2016
Q2 		$1.69M Sell
40,261
-2,328
-5% -$115K 0.24% 96
2016
Q1 		$1.73M Buy
+42,589
New +$1.82M 0.23% 105

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Portolan Capital Management's AGIO Position: Q3 2016 in Review

Portolan Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 40,261 shares — an estimated $1.69M sold.

Portolan Capital Management first reported a position in AGIO in Q1 2016 and held it in 2 quarters. The position peaked at $1.73M in Q1 2016. 163 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • Portolan Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Portolan Capital Management sold 40,261 Agios Pharmaceuticals shares in Q3 2016, an estimated $1.69M.
  • Portolan Capital Management first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Portolan Capital Management's Agios Pharmaceuticals position peaked at $1.73M in Q1 2016.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on Portolan Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.